Abeona sells priority review voucher for $155M

Abeona Therapeutics has entered into a definitive asset purchase agreement to sell its rare pediatric disease priority review voucher (PRV) for gross proceeds of $155 million upon closing of the transaction.

Abeona was awarded the PRV following the recent approval of Zevaskyn, an autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, a serious and debilitating genetic skin disease. Zevaskyn is the only FDA-approved product to treat RDEB wounds with a single application.

Abeona says that Zevaskyn will become available to treat patients beginning third quarter of 2025, and the company anticipates it becoming profitable in early 2026.

“With proceeds from this PRV sale, we have sufficient cash for more than two years of operating expenses without the need for capital infusion and not accounting for Zevaskyn sales,” said Joe Vazzano, Abeona CFO.

The buyer of the PRV was not disclosed. The voucher allows the recipient company to obtain FDA priority NDA or BLA review for product or indication, which can speed market entry by at least four months.